Companies / ACW

ACTINOGEN MEDICAL LIMITED

ASX:ACWPharmaceuticals, Biotechnology & Life Sciences
3.72B shares on issueAppendix 2A · as of 28 July 2026$0.042price · delayed$159.8Mmarket cap · indicative
F
Dilution grade

Runway under 2 quarters; share count grew 37% in 24 months; options/rights overhang 37% of shares

Cash runway1.5 quarters of funding
Share-count growth (24m)37.3%
Raise cadence (24m)2 cash raises
Options & rights overhang36.9% of shares
In-the-money supply10.5% of shares
Pending proposed issuesnone

ACTINOGEN MEDICAL LIMITED's ordinary share count grew 37.3% between July 2024 and July 2026, to 3.72B shares. The company raised capital twice in that period for total proceeds of A$27.9M, most recently a A$16.8M placement and SPP in January 2026. Options and rights on issue could convert into 1.37B new shares, equal to 36.9% of the current share count, of which 10% are in the money at the current share price; the nearest expiry is September 2026. At the March 2026 quarter the company reported A$11.6M in available cash, about 1.5 quarters of funding at its recent spending rate. No proposed securities issues (Appendix 3B) are currently pending.

AI-generated summary of this page's cited filings · updated 28 July 2026
Email me when this grade changes
Alerts are coming soon — this opens a pre-filled email that puts you on the list.
36.9%
Max option dilution
10.5%
ITM option dilution
1
Raises · last 12 months
1.5 qtrs
Cash cover · under 2 quarters

Shares on issue — last 2 years

Ordinary shares on issue
Weekly counts from ASX records. Dots mark cash capital raises. Latest count 3.72B per Appendix 2A (28 July 2026).
3.21B3.40B3.58BDec 24Sept 25July 26Cash raise · 28 Jan 2026

Cash runway

1.5 qtrs
Less than two quarters of funding at the recent spend rate — near-term funding pressure.
$11.6M available cash at quarter ended 31 Mar 2026 · Runway is computed from Appendix 4C/5B filings and announced raise proceeds.
Paid plan
Cash runway history
Quarterly cash, net spend and cover trend from every Appendix 4C/5B on record up to 31 Mar 2026.
Join the waitlist

Issuance timeline

Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)

DateFormSecurityTotal on issue afterSource
28 July 20262A · quoted issueACW : ORDINARY FULLY PAID3.72BAppendix 2A
21 July 20262A · quoted issueACW : ORDINARY FULLY PAID3.72BAppendix 2A
24 June 20262A · quoted issueACW : ORDINARY FULLY PAID3.72BAppendix 2A
18 June 20262A · quoted issueACW : ORDINARY FULLY PAID3.66BAppendix 2A
21 May 20262A · quoted issueACW : ORDINARY FULLY PAID3.66BAppendix 2A
Paid plan
Full issuance history
Every quoted and unquoted issue and cancellation on record, plus unquoted securities (Appendix 4.2).
Join the waitlist

Capital raises

2 cash raises in the last 24 months · 1 in the last 12 months

$16.8M
Placement and SPP
28 Jan 2026 COMPLETE
Paid plan
Full raise history
Issue price, discount, brokers, purpose and tranche detail for every raise on record.
Join the waitlist

Pending proposed issues

No proposed issues (Appendix 3B) currently pending.

Options & convertible securities

36.9%
Total overhang · of current shares
10.5%
In the money · at current price
1.37B
Potential new shares
Sept 2026
Nearest expiry
Paid plan
Per-line options & expiry cliffs
Each option line — code, strike, expiry, quantity and ITM value — plus the expiry-cliff chart.
Join the waitlist

Director dealings

DateDirectorTypeSharesOptionsValueSource
24 June 2026Dr George MorstynOther3.0M——3Y notice
24 June 2026Dr Nicki VasquezOther3.0M——3Y notice
24 June 2026Mr Malcolm McComasOther3.0M——3Y notice
Paid plan
Full dealing history
Every change-of-director's-interest notice on record, with direction and consideration.
Join the waitlist

Ownership

Free account
Top-20 holders & substantial holder notices
Top-20 register snapshot and substantial-holder movements, each linked to its source notice.
Sign up free — coming soon

Latest announcements

28 July 2026Application for quotation of securities - ACW
21 July 2026Application for quotation of securities - ACW
19 July 2026$PXanamem depression trial published in British J Psychiatry
13 July 2026Notification of buy-back - ACW
12 July 2026ACW AAIC poster presentation of XanaMIA trial baseline data
7 July 2026ACW senior management presentation at AAIC & internationally
25 June 2026Becoming a substantial holder
24 June 2026Appendix 3Y x 5
24 June 2026Application for quotation of securities - ACW
23 June 2026Results of Meeting
18 June 2026Application for quotation of securities - ACW
17 June 2026$PACW third positive XanaMIA trial data committee review
31 May 2026ACW presents XanaMIA population and screening data at ADRF
27 May 2026$PActinogen receives positive scientific advice from EMA
21 May 2026Application for quotation of securities - ACW
21 May 2026Letter to Shareholders, Notice of GM & Proxy Form
18 May 2026Application for quotation of securities - ACW
13 May 2026ACW CEO options exercise and expiry reminder
13 May 2026Appendix 3Y - Dr Steven Gourlay
13 May 2026Application for quotation of securities - ACW

Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 July 2026.